SGLT-2抑制剂对糖尿病肾病的保护作用的研究进展

Research progress on the protective effect of SGLT-2 inhibitors on diabetic nephropathy

糖尿病肾病(diabetic nephropathy,DN)是糖尿病严重的并发症之一,部分患者会进展为终末期肾病(end-stage renal disease,ESRD),病死率明显高于不伴肾病的糖尿病患者。钠-葡萄糖转运蛋白2(sodium-glucose transporter 2,SGLT-2)抑制剂是一种新型降糖药物,目前研究发现,除降糖作用外还有减轻体重、改善血压、减少尿蛋白、降低血尿酸、改善肾小球超滤和氧化应激、抑制炎症和纤维化等作用,可以通过多种途径保护肾脏,有望用于预防及延缓DN的发生和发展。未来可以进一步探索SGLT-2抑制剂的肾保护机制,亦可以基于其肾保护作用扩展应用于非DN患者。

Diabetic nephropathy(DN)is one of the serious complications of diabetes.Some patients will progress to end-stage renal disease(ESRD),and the mortality rate is significantly higher than that of diabetics without DN.Developed originally as glucose-lowering drugs by enhancing urinary glucose excretion,sodium-glucose transporter 2(SGLT-2)inhibitors also lower many other renal risk factors such as body weight,blood pressure,albuminuria,uric acid and improve renal oxygenation,intra-renal inflammation thereby slowing the progression of kidney function decline.Future research can explore the mechanism of SGLT-2 inhibitors’protective effect on kidney,and its potential in the treatment of non-diabetic kidney disease.